RepliCel Life Sciences Inc. Share Price Toronto S.E.
Equities
RP
CA76027P4006
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CAD | -.--% | -21.43% | -15.38% |
Sales 2022 | 354K 257K 21.46M | Sales 2023 | 354K 257K 21.46M | Capitalization | 3.87M 2.81M 235M |
---|---|---|---|---|---|
Net income 2022 | - 0 0 | Net income 2023 | - 0 0 | EV / Sales 2022 | 9.26 x |
Net Debt 2022 | 300K 218K 18.2M | Net Debt 2023 | 797K 578K 48.34M | EV / Sales 2023 | 13.2 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-11.3
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.48% |
6 months | -31.25% | ||
Current year | -15.38% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 14/18/14 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 22/10/22 |
Peter Lewis
BRD | Director/Board Member | 69 | 27/11/27 |
Rolf Hoffmann
FOU | Founder | 63 | - |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- REPCF Stock
- RP Stock